Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s

Infectious Disease in Obstetrics and Gynecology

Volumn 12, Issue 2, 2004, Pages 99-108

  Mårdh, Per Anders ^a   Wågström, Jolanta ^b   Landgren, Maria ^b   Holmén, Jan ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Apoteket AB   (Sweden)

^c Hospital Pharmacy   (Sweden)

Author keywords

Antifungals Sales Volumes; Epidemiology of VVC and RVVC; Over the Counter Azole Products; Prescriptions of anti Candida Drugs

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; CONTRACEPTIVE AGENT; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; MICONAZOLE; NON PRESCRIPTION DRUG; PEVARYL DEPOT;

ARTICLE; CANDIDA; COMMUNITY; CORRELATION ANALYSIS; DATA BASE; DEMOGRAPHY; DRUG DISTRIBUTION; DRUG MARKETING; HEALTH CARE; HEALTH CENTER; INTRAUTERINE CONTRACEPTIVE DEVICE; ORAL CONTRACEPTION; PHARMACY; POPULATION DENSITY; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL MODEL; SWEDEN; TIME; VAGINA CANDIDIASIS;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AZOLES; CANDIDIASIS, VULVOVAGINAL; DATABASES; DEMOGRAPHY; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; MIDDLE AGED; PHARMACIES; PRESCRIPTIONS, DRUG; RECURRENCE; RURAL POPULATION; SELF MEDICATION; SEXUAL BEHAVIOR; SWEDEN; URBAN POPULATION;

EID: 10944258915     PISSN: 10647449     EISSN: None     Source Type: Journal    
DOI: 10.1080/10647440400003972     Document Type: Article

References (23)

1. Eckert LO, Hawes SW, Stevens CE, et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998;92:757-65
2. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnosis and therapeutic considerations. Am J Obstet Gynecol 1998;178:203-11
3. Mårdh P-A, Rodrigues AG, Genç M, et al. Facts and myths on recurrent Vulvovaginal candidosis - epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD/AIDS 2002;13:522-39
4. Schaaf VM, Perez-Stable EJ, Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 1990;150:1929-33
5. Mårdh P-A, Tchoudomirova E, Elshibly S, Hellberg D. Symptoms and signs in single and mixed genital infections in attendees of family planning and youth clinics. Int J Gynaecol Obstet 1998; 63:145-52
6. Ledger WJ. Current problems in the diagnosis and treatment of Candida vaginitis. Ital J Obstet Gynecol 1999;11:25-9
7. Mårdh P-A, Novikova N. RVVC - a puzzling condition. In Kohl PK, Jod SJ, eds. Proceedings of the International Congress on Sexually Transmitted Infections (ISSTDR/IUSTI), Berlin, 2001. Bologna: Monduzzi Editore, 2001:147-52
8. Mårdh P-A, Wågström J, Landgren M, Holmén J. Usage of antifungal drugs for therapy of genital Candida infections, purchased as over the counter products or by prescription: 1. Analyses of a unique database. Infect Dis Obstet Gynecol 2004;12:000-00
9. ACS, Apotekets Centrala Statistik [database]. Apoteket AB, Sweden
10. Brown D Jr, Binder GL, Gardner HL, Wells J. Comparison of econazole and clotrimazole in the treatment of vulvovaginal candidiasis. Obstet Gynecol 1980;56:121-3
11. Sobel JD, Muller G. Ketoconazole prophylaxis in experimental vaginal candidiasis. Antimicrob Agents Chemother 1984;25:281-2
12. Calderon-Marquez JJ. Itraconazole in the treatment of vaginal candidosis and the effect treatment of the sexual partner. Rev Infect Dis 1987;9:S143-5
13. Geiger AM, Foxman B. Risk factors in vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996;7:182-7
14. Mårdh P-A, Novikova N, Stukalova E. Colonisation of extragenital sites by Candida in cases of recurrent vulvovaginal candidosis. Br J Obstet Gynaecol 2003;110:934-7
15. Rodrigues AG, Mårdh P-A, Pina Vaz C, et al. Is lack of concurrence of bacterial vaginosis and candidosis explained by presence of bacterial amines? Am J Obstet Gynecol 1999;181:367-70
16. Rodrigues A, Pina-Vaz C, Mårdh P-A, et al. In vitro effect of fibrinogen on Candida albicans germ tube formation. APMIS 1999;107:1020-2
17. Sihro S, Ahonen R, Mikander H, Hemminki E. Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization. Fam Pract 2000;17:145-9
18. Garcia PJ, Gotuzzo E, Hughes JP, Holmes KK. Syndrome management of STDs in pharmacies: evaluation and randomized intervention trial. Sex Transm Infect 1998;74:153-8
19. Whittington Z, Cantrill J, Hassell K, et al. Community pharmacy management of minor conditions - the 'care of the chemist' scheme. Pharm J 2001;266:425-8
20. Cederlund H, Mårdh P-A. Antimicrobial activities of non-antibiotic drugs. J Antimicrob Chemother 1993;32:355-65
21. Pina-Vaz C, Sansonetty F, Martinez-de-Oliveira J, et al. Antifungal effect of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol 2000;49:831-40
22. Apoteket AB. Svensk Läkemedellsstatistik-99 [Swedish Medical Drug Statistics]. Sweden: Apoteket AB, 1999
23. Miller G, Irving D, Robinson A, et al. Psychological factors associated with recurrent vaginal candidiasis: a preliminary study. Sex Transm Infect 1998;74:334-8